United Kingdom (UK)
Recombinant monoclonal antibody to CD38. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from phage display MU1053.
UniProt Accession Number of Target Protein: P28907
Alternative Name(s) of Target: Cluster of Differentiation 38; ADP-Ribosyl Cyclase 1; ADPRC1; ADPRC 1; 2-Phospho-Cyclic-ADP-Ribose Transferase; Cyclic ADP-Ribose Hydrolase 1; 2-Phospho-ADP-Ribosyl Cyclase; NAD(+) Nucleosidase; ADP-Ribose Transferase; Ecto-Nicotinamide Adenine Dinucleoti
Immunogen: The C-terminal domain of human CD38 (residue 45–300) was expressed and produced in a yeast expression system. The purified recombinant protein was used as an antigen to immunize llamas. Phage display technology was used to obtain positive clones against CD38.
Specificity: MU1053 binds an epitope close to the C-terminal region of CD38. The residues composing this epitope are: N120, K121, F135, Q139, M142, D202, V203, H205, Q236, T237, E239, W241, Q272, S274, K276, I278, F284, C287, V288, P291, E292, S294, C296.
Application Notes: The nanobody MU1053 has been crystallised with CD38, and has been used to target molecules to CD38. Tagging the nanobody with fluorescent proteins allows the quantification of CD38 expression by flow cytometry, which can be used to identify malignant multiple myeloma cells, which have higher CD38 expression. Further, a form of MU1053 conjugated to a toxin has been developed as a potential therapeutic agent to selectively kill CD38+ cells.
Antibody first published in:
Li et al. Immuno-targeting the multifunctional CD38 using nanobody. Sci Rep. 2016 Jun 2;6:27057 PMID:27251575
Note on publication:
Describes increased CD38 expression in malignant cells and its potential as a drug target for cancer therapy.